

- in infectious diseases, 764, 766t
reference values for, 2755t
- Erythrocytosis, 399. *See also* Polycythemia
in cyanotic CHD, 1523
etiology of, 673, 673t, 1873
in hemoglobinopathy, 637
paraneoplastic, 612, 612t
stress (spurious), 673
testosterone therapy and, 2372–2373
- Erythroderma, 353
drug-induced, 353–354
etiology of, 353–354, 353t, 354t
in toxic shock syndrome, 780t, 782. *See also*
Toxic shock syndrome (TSS)
- Erythroid hyperplasia, 397, 397f, 626, 637
- Erythroleukemia, 81e-9f, 639
- Erythromelalgia (erythromalgia), 674, 677,
1648f, 1650
- Erythromycin
for acne vulgaris, 352
for actinomycosis, 1091t
action of, 931, 931t
adverse effects of, 261, 284, 2023, 2029
for bacillary angiomatosis, 832t, 1081t
for bite-wound infections, 167e-3t
for bronchiectasis prophylaxis, 1696
for *C. pneumoniae* infections, 1174
for *C. trachomatis* infection, 1171
for *Campylobacter* infections, 1061
for cellulitis, 832t
for chancroid, 1013
for cholera, 1064
for diphtheria, 979
for donovanosis, 198e-2t
drug interactions of, 34t, 943
azoles, 246e-3t
cisapride, 42t
cyclosporine, 42t
digoxin, 42t
PDE-5 inhibitors, 328
statins, 34t
theophylline, 1677
for gastroparesis, 260, 260t
indications for, 940t
for Lyme disease, 1153, 1153f
for pertussis, 1024t
in pregnancy and lactation, 937t
prophylactic, 945t
for psittacosis, 1173
for relapsing fever, 1148, 1148f
resistance to, 931t, 940t, 966
- Erythron, 392
- Erythrophagocytosis, in aggressive lymphoma,
81e-11f
- Erythroplakia, 237, 240t, 503
- Erythropoiesis
ineffective, 281, 398, 2000
iron-deficient, 627, 627f
megaloblastic, 81e-8f
physiology of, 392–393, 392f
- Erythropoietic protoporphyria (EPP)
clinical features of, 363, 390, 2522t,
2532–2533, 2533f
diagnosis of, 390, 2522t, 2533
global considerations in, 2521
pathophysiology of, 2522f
treatment of, 390, 2533
- Erythropoietin
action of, 392
in anemia, 392–393, 392f, 629–630
deficiency of, 398
ectopic production of, 400, 612
elevated, 400
in hematopoietic differentiation, 89e-3f
plasma, 392
pNET secreting, 559t, 571
regulation of production of, 392–393, 392f
- Erythropoietin therapy
adverse effects of, 103e-25, 668t
for anemia, 399
for anemia in chronic kidney disease, 1818
for chemotherapy-induced anemia,
103e-24–25
depot formulations, 103e-25
- for hypoproliferative anemia, 631
iron demand and, 631
for orthostatic hypotension, 146, 2644
- ESBL (extended-spectrum β -lactamase), 933,
1026
- Escape mutants, in HBV, 2008
- Eschar
in anthrax, 134t, 261e-2, 261e-3f
burn, 166e-2, 166e-2f
characteristics of, 127, 827f
in ecthyma gangrenosum, 132t
in rickettsialpox, 132t, 135
in scrub typhus, 128t, 135
- Escharate virus, 1309t
- Escherichia coli*
adherence of, 145e-2, 145e-2t, 852, 863
antibiotic resistance in, 807, 862, 934, 941t,
1026–1027
commensal strains, 1027
epidemiology of, 1025
extraintestinal pathogenic strains, 1027–1028
genome of, 776
host interactions of, 1025–1026, 1025t
intestinal pathogenic strains, 1028t,
1029–1030
enteroaggregative, 1031
enterohemorrhagic. *See* Enterohemorrhagic
E. coli (EHEC)
enteroinvasive, 1031
enteropathogenic, 852, 1030–1031
enterotoxigenic. *See* Enterotoxigenic *E. coli*
(ETEC)
Shiga toxin–producing. *See* Shiga toxin–
producing *E. coli* (STEC)
laboratory identification of, 150e-2t
pili of, 145e-2, 863
structure and function of, 1025
toxin production by, 853
virulence factors of, 863, 1025
- Escherichia coli* infections, 1027
burn-wound, 166e-1
in cancer patient, 486, 486f, 486t
epidemiology of, 1025
extraintestinal
abdominal/pelvic, 846, 1028
bacteremia, 1029
cellulitis, 1028–1029
ecthyma gangrenosum, 369
endovascular, 1029
intrauterine, 50
meningitis, 1028
osteomyelitis, 839
perinephric abscess, 851
peritonitis, 288
pneumonia, 1028
treatment of, 1029
urinary tract, 862, 863, 866, 1028
- intestinal. *See also* Diarrhea, infectious;
Travelers' diarrhea
clinical features of, 266, 1028t
diagnosis of, 267, 1031
enterohemorrhagic: strain O157:H7,
267, 856, 1030, 1031, 1863. *See also*
Hemolytic-uremic syndrome (HUS)
epidemiology of, 855
etiology of, 1030–1031
vs. IBD, 1956
Shiga toxin–producing, 1864
transmission of, 1030
treatment of, 1031
intraabdominal, 1099
sepsis and septic shock, 1752
in transplant recipient, 919, 924
treatment of, 940t
- Escitalopram
adverse effects of, 2710t
for depression, 64, 2602, 2710t, 2716
for generalized anxiety disorder, 2711
- Esmolol
for aortic dissection, 1641
for arrhythmias, 1479t
dosage of, 1479t
for hypertension in subarachnoid hemorrhage,
1787
- for hypertensive emergencies, 1627t
for ischemic heart disease, 1589t
overdosage/poisoning with, 473e-9t
- Esomeprazole
for GERD, 263
for peptic ulcer disease, 1920, 1920t
for ZES, 1929
- Esophageal atresia, 1904
- Esophageal cancer, 532
adenocarcinoma, 532–533, 533t
Barrett's esophagus and. *See* Barrett's
esophagus/metaplasia
clinical features of, 257, 533, 1904
deaths from, 467t, 532, 1903
diagnosis of, 533
endoscopic appearance of, 1907, 1907f
etiology of, 532–533, 532t, 533t
global considerations in, 532
H. pylori infection and, 1040
incidence of, 467t, 468, 532–533, 1903
prevention of, 476
prognosis of, 533
risk factors for, 262, 2725, 2730t
smokeless tobacco and, 476
squamous cell, 532–533, 532t
staging of, 1885f
treatment of, 91e-4, 533
- Esophageal disease, 1900
clinical features of
chest pain, 96t, 98, 1901, 1905
dysphagia, 256–257, 1901, 1904
globus sensation, 1901
heartburn, 262, 1876, 1900, 1901
indigestion, 262. *See also* Indigestion
odynophagia, 1901
regurgitation, 1901
water brash, 1901
congenital anomalies, 1904
dermatologic disorders and, 1911
diagnosis of, 1901–1902, 1902f
diverticula, 256, 259, 1903, 1903f
esophagitis. *See* Esophagitis
GERD. *See* Gastroesophageal reflux disease
(GERD)
hiatal hernia, 1902, 1902f
iatrogenic injury, 1910
mechanical trauma, 1910–1911
motility disorders, 1904
achalasia. *See* Achalasia
diffuse esophageal spasm, 256, 1905–1906,
1906f
obstruction, 1891–1892, 1893f
rings, 1902, 1902f
Schatzki's ring, 256, 1895, 1896f, 1902
stricture, 256, 1895, 1896f
structural disorders, 1902–1904, 1902f, 1903f
in systemic sclerosis, 2161
tumors, 1904. *See also* Esophageal cancer
varices. *See* Esophageal varices
webs, 1902–1903
- Esophageal manometry
in diffuse esophageal spasm, 1906, 1906f
in dysphagia, 257
in GERD, 262
indications for, 1901
normal, 1902f
- Esophageal pseudodiverticulosis, 1903, 1903f
- Esophageal spasm
chest pain in, 96t, 98
diffuse, 256, 1905–1906, 1906f
jackhammer esophagus, 1907f
- Esophageal varices
bleeding in, 276, 276t, 277, 2063–2064, 2064f
endoscopic findings in, 1890, 1890f
portal hypertension and, 2063
in superior vena cava syndrome, 1788
treatment of, 346e-1v, 1890–1891, 1890f,
2063–2064, 2064f
- Esophageal web, 532
- Esophagectomy, for esophageal cancer, 533
- Esophagitis
in cancer patient, 488
clinical features of, 106t, 256–257, 1909
corrosive, 1910